Skip to main content

Table 4 Laboratory parameters of COVID-19 patients stratified by Syndecan-1 level at ICU admission (cutoff: 813.8 ng/mL)

From: Syndecan-1, an indicator of endothelial glycocalyx degradation, predicts outcome of patients admitted to an ICU with COVID-19

  Syndecan-1 P
High level (N = 27) Low level (N = 22)
Tissue and endothelial damage
 Thrombomodulin (ng/mL) 5.1 (3.9–6.0) (27) 3.8 (3.3–4.2) (22) 0.002
Inflammation
 IL-1β (pg/mL) ↑ 9.1% (1/11) 25.0% (2/8) 0.763
 IL-2R (U/mL) 1284.0 (469.0–2029.0) (11) 1052.0 (639.5–1262.0) (9) 0.309
 IL-6 (pg/mL) 133.1 (52.6–343.1) (13) 18.0 (8.7–97.9) (12) 0.003
 IL-8 (pg/mL) 79.3 (11.5–177.0) (11) 24.0 (13.9–57.6) (8) 0.238
 IL-10 (pg/mL) 17.0 (2.5–33.7) (11) 4.3 (2.5–13.3) (8) 0.075
 TNFα (pg/mL) 16.9 (5.0–33.8) (10) 7.5 (6.3–9.5) (7) 0.042
Hematologic
  White blood cell count (× 109/L) 10.3 (6.6–19.0) (27) 11.4 (7.8–16.1) (19) 0.973
  Neutrophil count (× 109/L) 9.8 (5.9–18.5) (26) 8.7 (6.2–15.0) (19) 0.573
 Lymphocyte count (× 109/L) 0.5 (0.3–0.7) (27) 0.6 (0.4–1.0) (20) 0.079
 Red blood cell count (× 1012/L) ↓ 61.5% (16/26) 40.0% (8/20) 0.147
 Hemoglobin (g/L) ↓ 81.5% (22/27) 75.0% (15/20) 0.860
 Hematocrit (%) ↓ 61.5% (16/26) 35.0% (7/20) 0.074
 Platelet count (× 109/L) 73.0 (40.0–141.0) (27) 171.0 (111.0–247.0) (19) 0.002
Biochemical
 Glucose (mmol/L) 10.5 (7.6–13.8) (26) 9.3 (7.1–12.5) (19) 0.662
 Total cholesterol (mmol/L) 2.7 (2.3–3.4) (26) 3.3 (2.8–3.8) (20) 0.031
 HsCRP (mg/L) 113.9 (66.5–193.0) (20) 51.7 (17.9–94.2) (15) 0.043
 High-sensitive cardiac troponin I (pg/mL) ↑ 69.2% (18/26) 68.4% (13/19) 0.954
 Myoglobin (ng/mL) ↑ 69.2% (18/26) 21.1% (4/19) 0.001
 AST (U/L) ↑ 50.0% (13/26) 26.3% (5/19) 0.109
 LDH (U/L) ↑ 96.3% (26/27) 90.0% (18/20) 0.787
 CK (U/L) ↑ 50.0% (7/14) 14.3% (1/7) 0.266
 CK-MB (ng/mL) ↑ 50.0% (13/26) 0.0% (0/19)  < 0.001
 NT-proBNP (pg/mL) ↑ 88.0% (22/25) 78.9% (15/19) 0.691
 Ferritin (μg/L) ↑ 100.0% (5/5) 83.3% (5/6) 1.000
Coagulation
 Prothrombin time (s) 17.3 (15.8–21.3) (27) 15.1 (13.9–15.9) (18)  < 0.001
 Prothrombin activity (%) 58.0 (41.8–70.0) (26) 76.0 (69.5–91.3) (18)  < 0.001
 INR 1.4 (1.3–1.8) (26) 1.2 (1.1–1.3) (18)  < 0.001
 Fibrinogen (g/L) 3.6 (2.8–5.1) (27) 4.5 (3.5–5.4) (18) 0.397
 APTT (s) 45.4 (39.3–57.4) (27) 40.3 (33.9–44.0) (18) 0.011
 Thrombin time (s) 15.5 (14.7–17.7) (27) 15.4 (14.7–16.0) (18) 0.437
 D-dimer (μg/mL FEU) 7.1 (2.5–21.0) (26) 9.6 (1.3–18.5) (18) 0.589
 Fibrinogen degradation products (μg/mL) 44.7 (14.5–150.0) (12) 55.1 (4.0–77.7) (7) 0.592
 Antithrombin (%) 77.0 (57.3–86.5) (14) 82.0 (79.0–93.0) (9) 0.058
Other
 Procalcitonin (ng/mL) 1.8 (0.3–3.5) (10) 0.1 (0.1–0.4) (12) 0.006
 ESR (mm/h) ↑ 75.0% (3/4) 100.0% (5/5) 0.444
 aPLs positive 50.0% (2/4) 50.0% (1/2) 1.000
  1. Bold values indicate statistical significance
  2. Data are presented as median (Q1–Q3) (N) or % (n/N)
  3. COVID-19, coronavirus disease 2019; ICU, intensive care unit; IL, interleukin; TNF-α, tumor necrosis factor-alpha; hsCRP, high-sensitivity C-reactive protein; AST, aspartate transaminase; LDH, lactate dehydrogenase; CK, creatine kinase; CK-MB, creatine kinase-myoglobin band; NT-proBNP, N-terminal pro-brain natriuretic peptide; INR, international normalized ratio; APTT, activated partial thromboplastin time; ESR, erythrocyte sedimentation rate; aPLs, antiphospholipid antibodies